Jocelyn Booth

2.4k total citations
11 papers, 156 citations indexed

About

Jocelyn Booth is a scholar working on Oncology, Epidemiology and Immunology. According to data from OpenAlex, Jocelyn Booth has authored 11 papers receiving a total of 156 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Epidemiology and 3 papers in Immunology. Recurrent topics in Jocelyn Booth's work include CAR-T cell therapy research (9 papers), Nonmelanoma Skin Cancer Studies (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Jocelyn Booth is often cited by papers focused on CAR-T cell therapy research (9 papers), Nonmelanoma Skin Cancer Studies (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Jocelyn Booth collaborates with scholars based in United States, Germany and Australia. Jocelyn Booth's co-authors include Matthew G. Fury, Alexander Guminski, Jean Pascal Machiels, Danny Rischin, Christian U. Blank, Pierre I. Karakiewicz, Daniel Castellano, Petri Bono, Nicoletta Pirotta and Sevil Bavbek and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Jocelyn Booth

10 papers receiving 155 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jocelyn Booth United States 5 82 82 62 53 39 11 156
Jorge Dunstan Peru 7 132 1.6× 27 0.3× 16 0.3× 31 0.6× 12 0.3× 17 163
J. G. M. Segalla Brazil 8 80 1.0× 21 0.3× 53 0.9× 44 0.8× 22 0.6× 21 162
Varina R. Clark United States 3 249 3.0× 41 0.5× 34 0.5× 91 1.7× 10 0.3× 5 284
Kadzuki Nakabayashi Japan 6 30 0.4× 48 0.6× 92 1.5× 42 0.8× 7 0.2× 6 201
Serena Corsetti Italy 8 55 0.7× 17 0.2× 34 0.5× 28 0.5× 15 0.4× 19 112
Fernando Henao Spain 7 121 1.5× 18 0.2× 50 0.8× 37 0.7× 5 0.1× 24 198
Longde Lin China 7 55 0.7× 16 0.2× 12 0.2× 63 1.2× 8 0.2× 9 156
Janine Roy Germany 6 16 0.2× 13 0.2× 58 0.9× 57 1.1× 32 0.8× 11 174
Rachel Roberts‐Thomson Australia 8 74 0.9× 14 0.2× 20 0.3× 41 0.8× 5 0.1× 15 127
Yusheng Han China 8 119 1.5× 37 0.5× 37 0.6× 45 0.8× 2 0.1× 19 196

Countries citing papers authored by Jocelyn Booth

Since Specialization
Citations

This map shows the geographic impact of Jocelyn Booth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jocelyn Booth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jocelyn Booth more than expected).

Fields of papers citing papers by Jocelyn Booth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jocelyn Booth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jocelyn Booth. The network helps show where Jocelyn Booth may publish in the future.

Co-authorship network of co-authors of Jocelyn Booth

This figure shows the co-authorship network connecting the top 25 collaborators of Jocelyn Booth. A scholar is included among the top collaborators of Jocelyn Booth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jocelyn Booth. Jocelyn Booth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Khushalani, Nikhil I., Jocelyn Booth, Mark Salvati, et al.. (2024). A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma.. Journal of Clinical Oncology. 42(16_suppl). TPS9611–TPS9611. 2 indexed citations
2.
Migden, Michael R., Chrysalyne D. Schmults, Nikhil I. Khushalani, et al.. (2023). Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3. SKIN The Journal of Cutaneous Medicine. 7(2). s176–s176. 1 indexed citations
3.
Grob, Jean‐Jacques, Samantha Bowyer, Fiona Day, et al.. (2022). 818P Phase II confirmatory study of cemiplimab (350mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6. Annals of Oncology. 33. S921–S921. 2 indexed citations
4.
Rischin, Danny, Brett Hughes, Nicole Basset‐Séguin, et al.. (2021). 1066P Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results. Annals of Oncology. 32. S886–S887. 1 indexed citations
5.
Rischin, Danny, Nikhil I. Khushalani, Chrysalyne D. Schmults, et al.. (2020). Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.. Journal of Clinical Oncology. 38(15_suppl). 10018–10018. 26 indexed citations
6.
Rischin, Danny, Nikhil I. Khushalani, Alexander Guminski, et al.. (2020). Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up. SKIN The Journal of Cutaneous Medicine. 4(6). s124–s124. 1 indexed citations
7.
8.
Migden, Michael R., Nikhil I. Khushalani, Anne Lynn S. Chang, et al.. (2019). Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).. Journal of Clinical Oncology. 37(15_suppl). 6015–6015. 24 indexed citations
9.
Guminski, Alexander, Annette M. Lim, Nikhil I. Khushalani, et al.. (2019). Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up.. Journal of Clinical Oncology. 37(15_suppl). 9526–9526. 27 indexed citations
10.
Rischin, Danny, Michael R. Migden, Anne Lynn S. Chang, et al.. (2018). Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC).. Journal of Clinical Oncology. 36(15_suppl). 9519–9519. 5 indexed citations
11.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jorge Dunstan Breakdown of academic impact, for papers by J. G. M. Segalla Breakdown of academic impact, for papers by Varina R. Clark Breakdown of academic impact, for papers by Kadzuki Nakabayashi Breakdown of academic impact, for papers by Serena Corsetti Breakdown of academic impact, for papers by Fernando Henao Breakdown of academic impact, for papers by Longde Lin Breakdown of academic impact, for papers by Janine Roy Breakdown of academic impact, for papers by Rachel Roberts‐Thomson Breakdown of academic impact, for papers by Yusheng Han
Rankless by CCL
2026